Criado Paulo Ricardo, Criado Roberta Facchini Jardim, Maruta Celina Wakisaka, Reis Vitor Manoel Silva dos
Universidade de São Paulo, São Paulo, SP, Brazil.
An Bras Dermatol. 2015 Jan-Feb;90(1):74-89. doi: 10.1590/abd1806-4841.20153509.
Chronic urticaria has been explored in several investigative aspects in the new millennium, either as to its pathogenesis, its stand as an autoimmune or auto-reactive disease, the correlation with HLA-linked genetic factors, especially with class II or its interrelation with the coagulation and fibrinolysis systems. New second-generation antihistamines, which act as good symptomatic drugs, emerged and were commercialized over the last decade. Old and new drugs that may interfere with the pathophysiology of the disease, such as cyclosporine and omalizumab have been developed and used as treatments. The purpose of this article is to describe the current state of knowledge on aspects of chronic urticaria such as, pathophysiology, diagnosis and the current therapeutic approach proposed in the literature.
在新千年里,慢性荨麻疹已经在多个研究方面进行了探索,包括其发病机制、作为自身免疫性或自身反应性疾病的地位、与HLA相关遗传因素的相关性,特别是与II类基因的相关性,以及它与凝血和纤维蛋白溶解系统的相互关系。在过去十年中,作为有效的对症药物的新一代抗组胺药出现并实现了商业化。已经开发出可能干扰该疾病病理生理学的新旧药物,如环孢素和奥马珠单抗,并将其用作治疗药物。本文的目的是描述慢性荨麻疹在病理生理学、诊断以及文献中提出的当前治疗方法等方面的当前知识状态。